Aerobiotix has raised a $25 million of growth equity financing. The round was led by Vivo Capital with participation by Asahi Kasei Ventures.

Founded 2013, Aerobiotix has developed a novel suite of FDA 510(k) cleared hospital-based air decontamination products and its devices are supported by multiple peer-reviewed research studies. Aerobiotix devices, such as the operating-room based ILLUVIA system, are used by leading healthcare centers to reduce bacterial and viral contamination, including SARS-CoV-2 and other emerging pathogens.